Literature DB >> 6847334

Carbamazepine and its -10,11-epoxide metabolite in plasma and CSF. Relationship to antidepressant response.

R M Post, T W Uhde, J C Ballenger, D C Chatterji, R F Greene, W E Bunney.   

Abstract

Levels of carbamazepine and its -10,11-epoxide metabolite were measured in plasma and CSF of affectively ill patients treated only with carbamazepine for an average of 33 days at an average dosage of 1,055 mg/day. The CSF levels of carbamazepine were 2.06 micrograms/mL (ie, 31% of plasma levels, which equaled 6.55 micrograms/mL); CSF -10,11-epoxide concentrations averaged 0.91 micrograms/mL in 18 subjects (63% of those found in plasma). Carbamazepine levels in plasma or CSF were not related to degree of antidepressant or antimanic response. In contrast, concentrations of the -10,11-epoxide metabolite were correlated with the degree of antidepressant response. This preliminary study suggests the possibility that the -10,11-epoxide metabolite of carbamazepine may be related to the degree of clinical efficacy in affectively ill patients and may thus possess active psychotropic properties in man in addition to its reported anticonvulsant effects in animals.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6847334     DOI: 10.1001/archpsyc.1983.04390010083010

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  14 in total

Review 1.  Therapeutic drug monitoring of psychotropic medications.

Authors:  P B Mitchell
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

2.  Interaction of carbamazepine and other drugs with adenosine (A1 and A2) receptors.

Authors:  Y Fujiwara; M Sato; S Otsuki
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 3.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 4.  Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice.

Authors:  Robert M Post; Terence A Ketter; Thomas Uhde; James C Ballenger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 5.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

6.  Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites.

Authors:  T B Kudriakova; L A Sirota; G I Rozova; V A Gorkov
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

7.  Lack of effect of chronic carbamazepine on brain somatostatin in the rat.

Authors:  S R Weiss; T Nguyen; D R Rubinow; C J Helke; P K Narang; R M Post; D M Jacobowitz
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

8.  Epileptic seizure disorders. Developments in diagnosis and therapy.

Authors:  E Niedermeyer; W Froescher; R S Fisher
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

9.  Effects of carbamazepine on noradrenergic mechanisms in affectively ill patients.

Authors:  R M Post; D R Rubinow; T W Uhde; J C Ballenger; C R Lake; M Linnoila; D C Jimerson; V Reus
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

10.  Concentration-effect relationships with carbamazepine and its epoxide on psychomotor and cognitive function in epileptic patients.

Authors:  R A Gillham; N Williams; K Wiedmann; E Butler; J G Larkin; M J Brodie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-07       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.